Clinical trial
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AGA2115 in Adult Healthy Volunteers
NCT06086613 is registered in ClinicalTrials.gov with Angitia Incorporated Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AGA2115 in Adult Healthy Volunteers
- Lead sponsor
- Angitia Incorporated Limited
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 3, 2023
- Completion date
- October 17, 2024
- Enrollment
- 72 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.